AMPH Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 21.14% compared to Amphastar Pharmaceuticals's net margin of 14.23%. Amphastar Pharmaceuticals's return on equity of 23.56% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Amphastar Pharmaceuticals has a consensus price target of $62.60, signalling upside risk potential of 60.33%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.02 which suggests that it could grow by 46.76%. Given that Amphastar Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Amphastar Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Amphastar Pharmaceuticals has a beta of 0.824, which suggesting that the stock is 17.563% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $191.2M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Amphastar Pharmaceuticals's net income of $40.4M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 12.10x while Biomarin Pharmaceutical's PE ratio is 40.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.63x versus 4.77x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 21.14% compared to Amphastar Pharmaceuticals's net margin of 8.48%. Amphastar Pharmaceuticals's return on equity of 23.56% beat Eli Lilly and's return on equity of 66.4%.

Amphastar Pharmaceuticals has a consensus price target of $62.60, signalling upside risk potential of 60.33%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.84%. Given that Amphastar Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Amphastar Pharmaceuticals is more attractive than Eli Lilly and.

Amphastar Pharmaceuticals has a beta of 0.824, which suggesting that the stock is 17.563% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.67% to investors and pays a quarterly dividend of $1.30 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amphastar Pharmaceuticals quarterly revenues are $191.2M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Amphastar Pharmaceuticals's net income of $40.4M is lower than Eli Lilly and's net income of $970.3M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 12.10x while Eli Lilly and's PE ratio is 84.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.63x versus 17.30x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 21.14% compared to Amphastar Pharmaceuticals's net margin of -49.65%. Amphastar Pharmaceuticals's return on equity of 23.56% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Amphastar Pharmaceuticals has a consensus price target of $62.60, signalling upside risk potential of 60.33%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Amphastar Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals has a beta of 0.824, which suggesting that the stock is 17.563% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $191.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amphastar Pharmaceuticals's net income of $40.4M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 12.10x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.63x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of 21.14% compared to Amphastar Pharmaceuticals's net margin of 6.69%. Amphastar Pharmaceuticals's return on equity of 23.56% beat Viemed Healthcare's return on equity of 8.88%.

Amphastar Pharmaceuticals has a consensus price target of $62.60, signalling upside risk potential of 60.33%. On the other hand Viemed Healthcare has an analysts' consensus of -- which suggests that it could grow by 58.05%. Given that Amphastar Pharmaceuticals has higher upside potential than Viemed Healthcare, analysts believe Amphastar Pharmaceuticals is more attractive than Viemed Healthcare.

Amphastar Pharmaceuticals has a beta of 0.824, which suggesting that the stock is 17.563% less volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.781%.

Amphastar Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals pays -- of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals quarterly revenues are $191.2M, which are larger than Viemed Healthcare quarterly revenues of $58M. Amphastar Pharmaceuticals's net income of $40.4M is higher than Viemed Healthcare's net income of $3.9M. Notably, Amphastar Pharmaceuticals's price-to-earnings ratio is 12.10x while Viemed Healthcare's PE ratio is 31.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals is 2.63x versus 1.54x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.